US6362325B1
(en)
|
1988-11-07 |
2002-03-26 |
Advanced Research And Technology Institute, Inc. |
Murine 4-1BB gene
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
US6355476B1
(en)
|
1988-11-07 |
2002-03-12 |
Advanced Research And Technologyinc |
Nucleic acid encoding MIP-1α Lymphokine
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
US5821332A
(en)
|
1993-11-03 |
1998-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor on the surface of activated CD4+ T-cells: ACT-4
|
US6051227A
(en)
|
1995-07-25 |
2000-04-18 |
The Regents Of The University Of California, Office Of Technology Transfer |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
US6210669B1
(en)
|
1996-10-11 |
2001-04-03 |
Bristol-Myers Squibb Co. |
Methods and compositions for immunomodulation
|
US7112655B1
(en)
|
1997-02-27 |
2006-09-26 |
Japan Tobacco, Inc. |
JTT-1 protein and methods of inhibiting lymphocyte activation
|
JP3521382B2
(ja)
|
1997-02-27 |
2004-04-19 |
日本たばこ産業株式会社 |
細胞間接着及びシグナル伝達を媒介する細胞表面分子
|
CA2305350C
(en)
|
1997-09-23 |
2015-04-07 |
Bundesrepublik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-Instituts |
Costimulating polypeptide of t cells, monoclonal antibodies, and the preparation and use thereof
|
DE19821060A1
(de)
|
1997-09-23 |
1999-04-15 |
Bundesrepublik Deutschland Let |
Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
|
ES2315008T5
(es)
|
1998-02-24 |
2012-03-06 |
Sisters Of Providence In Oregon |
Agente de unión a receptor ox-40 para su uso en métodos de mejora de la respuesta inmune espec�?fica de ant�?geno tumoral.
|
ES2340745T3
(es)
|
1998-12-23 |
2010-06-08 |
Pfizer Inc. |
Anticuerpos monoclonales humanos contra ctla-4.
|
EE05627B1
(et)
|
1998-12-23 |
2013-02-15 |
Pfizer Inc. |
CTLA-4 vastased inimese monoklonaalsed antikehad
|
PT1210428E
(pt)
|
1999-08-23 |
2015-07-21 |
Genetics Inst Llc |
Pd-1, um recetor para b7-4 e suas utilizações
|
EP1212422B1
(en)
|
1999-08-24 |
2007-02-21 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
JP2003520828A
(ja)
|
2000-01-27 |
2003-07-08 |
ジェネティクス インスティテュート,エルエルシー |
Ctla4(cd152)に対する抗体、これを含む結合体、およびその使用
|
DE60317677T2
(de)
|
2002-06-13 |
2008-10-30 |
Crucell Holland B.V. |
Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
|
PL375144A1
(en)
|
2002-07-30 |
2005-11-28 |
Bristol-Myers Squibb Company |
Humanized antibodies against human 4-1bb
|
CN101899114A
(zh)
|
2002-12-23 |
2010-12-01 |
惠氏公司 |
抗pd-1抗体及其用途
|
CA2517145C
(en)
|
2003-03-05 |
2017-08-01 |
Halozyme, Inc. |
Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
|
KR20060079180A
(ko)
|
2003-07-02 |
2006-07-05 |
노보 노르디스크 에이/에스 |
Nk 세포 활성을 조절하기 위한 조성물 및 방법
|
ES2619171T3
(es)
|
2003-07-24 |
2017-06-23 |
Innate Pharma S.A. |
Métodos y composiciones para aumentar la eficacia de anticuerpos terapéuticos utilizando compuestos para la potenciación de linfocitos NK
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
EP1791868B1
(en)
|
2004-07-01 |
2011-02-23 |
Novo Nordisk A/S |
Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
|
EP1831258B2
(en)
|
2004-12-28 |
2023-06-07 |
Innate Pharma S.A. |
Monoclonal antibodies against nkg2a
|
EP1836225B1
(en)
|
2005-01-06 |
2011-11-02 |
Novo Nordisk A/S |
Kir-binding agents and methods of use thereof
|
JP5855326B2
(ja)
|
2005-01-06 |
2016-02-09 |
ノヴォ ノルディスク アー/エス |
抗kir組み合わせ治療および方法
|
ES2432091T5
(es)
|
2005-03-25 |
2022-03-18 |
Gitr Inc |
Moléculas de unión GITR y usos de las mismas
|
CA2970873C
(en)
|
2005-05-09 |
2022-05-17 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
CN104356236B
(zh)
|
2005-07-01 |
2020-07-03 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
AU2006301163B2
(en)
|
2005-10-14 |
2012-02-23 |
Innate Pharma |
Compositions and methods for treating proliferative disorders
|
CA2647282A1
(en)
|
2006-04-05 |
2007-10-11 |
Pfizer Products Inc. |
Ctla4 antibody combination therapy
|
JP5829004B2
(ja)
|
2006-06-30 |
2015-12-09 |
ノボ・ノルデイスク・エー/エス |
抗nkg2a抗体とその使用
|
CN105037549B
(zh)
|
2007-01-11 |
2018-09-28 |
诺和诺德公司 |
抗-kir抗体、制剂及其应用
|
EP2703011A3
(en)
|
2007-05-07 |
2014-03-26 |
MedImmune, LLC |
Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
JP2008278814A
(ja)
|
2007-05-11 |
2008-11-20 |
Igaku Seibutsugaku Kenkyusho:Kk |
アゴニスティック抗ヒトgitr抗体による免疫制御の解除とその応用
|
EP3222634A1
(en)
|
2007-06-18 |
2017-09-27 |
Merck Sharp & Dohme B.V. |
Antibodies to human programmed death receptor pd-1
|
ES2591281T3
(es)
|
2007-07-12 |
2016-11-25 |
Gitr, Inc. |
Terapias de combinación que emplean moléculas de enlazamiento a GITR
|
BRPI0815368A2
(pt)
|
2007-08-21 |
2015-02-10 |
Amgen Inc |
"proteinas c-fms humanas a antigeno"
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
MX2010007935A
(es)
|
2008-01-24 |
2010-08-23 |
Novo Nordisk As |
Anticuerpo monoclonal humanizado anti-nkg2a humano.
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
CN102702358B
(zh)
|
2008-03-14 |
2016-02-17 |
天士力创世杰(天津)生物制药有限公司 |
针对csf-1r的抗体
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
US8709411B2
(en)
|
2008-12-05 |
2014-04-29 |
Novo Nordisk A/S |
Combination therapy to enhance NK cell mediated cytotoxicity
|
PE20120341A1
(es)
|
2008-12-09 |
2012-04-24 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
|
US8709424B2
(en)
|
2009-09-03 |
2014-04-29 |
Merck Sharp & Dohme Corp. |
Anti-GITR antibodies
|
ES2681214T3
(es)
|
2009-09-30 |
2018-09-12 |
Memorial Sloan-Kettering Cancer Center |
Inmunoterapia de combinación para el tratamiento del cáncer
|
KR101573109B1
(ko)
|
2009-11-24 |
2015-12-01 |
메디뮨 리미티드 |
B7―h1에 대한 표적화된 결합 물질
|
WO2011140249A2
(en)
|
2010-05-04 |
2011-11-10 |
Five Prime Therapeutics, Inc. |
Antibodies that bind csf1r
|
KR101846590B1
(ko)
|
2010-06-11 |
2018-04-09 |
교와 핫꼬 기린 가부시키가이샤 |
항 tim-3 항체
|
WO2011159877A2
(en)
|
2010-06-18 |
2011-12-22 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
|
MY171312A
(en)
|
2010-08-23 |
2019-10-08 |
Univ Texas |
Anti-ox40 antibodies and methods of using the same
|
EA035033B1
(ru)
|
2010-11-22 |
2020-04-20 |
Иннейт Фарма Са |
Способ лечения гематологического предракового или гематологического ракового заболеваний
|
EP2710137B1
(en)
|
2011-03-10 |
2018-09-19 |
Provectus Pharmatech, Inc. |
A combination of rose bengal and anti-ctla4 antibody for use in the treatment of cancer
|
CA2830442C
(en)
|
2011-03-31 |
2019-09-24 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antibodies directed against icos and uses thereof
|
CA2833636A1
(en)
|
2011-04-20 |
2012-10-26 |
Amplimmune, Inc. |
Antibodies and other molecules that bind b7-h1 and pd-1
|
AU2012260601B2
(en)
|
2011-05-25 |
2018-02-01 |
Innate Pharma, S.A. |
Anti-KIR antibodies for the treatment of inflammatory disorders
|
WO2013006490A2
(en)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to tim3
|
AU2012299421B2
(en)
|
2011-08-23 |
2016-02-04 |
Board Of Regents, The University Of Texas System |
Anti-OX40 antibodies and methods of using the same
|
WO2013039954A1
(en)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anti-gitr antibodies
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
LT2785375T
(lt)
|
2011-11-28 |
2020-11-10 |
Merck Patent Gmbh |
Anti-pd-l1 antikūnai ir jų panaudojimas
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
US9856320B2
(en)
|
2012-05-15 |
2018-01-02 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
|
CN115093480A
(zh)
|
2012-05-31 |
2022-09-23 |
索伦托药业有限公司 |
与pd-l1结合的抗原结合蛋白
|
KR101566538B1
(ko)
|
2012-06-08 |
2015-11-05 |
국립암센터 |
신규한 Th17 세포 전환용 에피토프 및 이의 용도
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
RS56624B1
(sr)
|
2012-10-02 |
2018-03-30 |
Bristol Myers Squibb Co |
Kombinacija anti-kir antitela i anti-pd-1 antitela u lečenju kancera
|
AU2014230741B2
(en)
|
2013-03-15 |
2017-04-13 |
Glaxosmithkline Intellectual Property Development Limited |
Anti-LAG-3 binding proteins
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
SG11201507781VA
(en)
|
2013-03-18 |
2015-10-29 |
Biocerox Prod Bv |
Humanized anti-cd134 (ox40) antibodies and uses thereof
|
EP2992017B1
(en)
|
2013-05-02 |
2020-11-18 |
AnaptysBio, Inc. |
Antibodies directed against programmed death-1 (pd-1)
|
JP6563906B2
(ja)
|
2013-05-31 |
2019-08-21 |
ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. |
Pd−1に結合する抗原結合蛋白質
|
CN104250302B
(zh)
|
2013-06-26 |
2017-11-14 |
上海君实生物医药科技股份有限公司 |
抗pd‑1抗体及其应用
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
KR102276644B1
(ko)
|
2013-09-04 |
2021-07-13 |
브리스톨-마이어스 스큅 컴퍼니 |
면역조절제로서 유용한 화합물
|
AU2013400609B9
(en)
|
2013-09-13 |
2020-03-05 |
Beigene Switzerland Gmbh |
Anti-PD1 antibodies and their use as therapeutics and diagnostics
|
RS64268B1
(sr)
|
2013-09-20 |
2023-07-31 |
Bristol Myers Squibb Co |
Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
|
CR20160319A
(es)
|
2013-12-12 |
2016-11-08 |
Jiangsu Hengrui Medicine Co |
Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
SG11201607969XA
(en)
|
2014-03-31 |
2016-10-28 |
Genentech Inc |
Anti-ox40 antibodies and methods of use
|
CN106132439A
(zh)
|
2014-03-31 |
2016-11-16 |
豪夫迈·罗氏有限公司 |
包含抗血管发生剂和ox40结合激动剂的组合疗法
|
US9850225B2
(en)
|
2014-04-14 |
2017-12-26 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
MX2016014434A
(es)
|
2014-05-13 |
2017-02-23 |
Chugai Pharmaceutical Co Ltd |
Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion.
|
NZ726513A
(en)
|
2014-05-28 |
2023-07-28 |
Memorial Sloan Kettering Cancer Center |
Anti-gitr antibodies and methods of use thereof
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
WO2016032334A1
(en)
|
2014-08-28 |
2016-03-03 |
Academisch Ziekenhuis Leiden H.O.D.N. Lumc |
Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations
|
MX2017003201A
(es)
|
2014-09-11 |
2017-05-23 |
Bristol Myers Squibb Co |
Inhibidores macrociclicos de las interacciones proteina/proteina de muerte programada 1 (pd-1)/pd-l1 y cd80(b7-1)/pd-l1.
|
JP6767362B2
(ja)
|
2014-09-16 |
2020-10-14 |
イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. |
リンパ球における阻害経路の中和
|
US10676523B2
(en)
|
2014-09-16 |
2020-06-09 |
Innate Pharma |
Treatment regimens using anti-NKG2A antibodies
|
TW201619200A
(zh)
|
2014-10-10 |
2016-06-01 |
麥迪紐有限責任公司 |
人類化抗-ox40抗體及其用途
|
US9732119B2
(en)
|
2014-10-10 |
2017-08-15 |
Bristol-Myers Squibb Company |
Immunomodulators
|
GB201419094D0
(en)
|
2014-10-27 |
2014-12-10 |
Agency Science Tech & Res |
Anti-TIM-3-antibodies
|
EP3212231B1
(en)
|
2014-10-27 |
2021-04-28 |
Agency For Science, Technology And Research |
Anti-tim-3 antibodies
|
LT3215532T
(lt)
|
2014-11-06 |
2020-01-10 |
F. Hoffmann-La Roche Ag |
Anti-tim3 antikūnai ir jų naudojimo būdai
|
US9856292B2
(en)
|
2014-11-14 |
2018-01-02 |
Bristol-Myers Squibb Company |
Immunomodulators
|
US9861680B2
(en)
|
2014-12-18 |
2018-01-09 |
Bristol-Myers Squibb Company |
Immunomodulators
|
US9944678B2
(en)
|
2014-12-19 |
2018-04-17 |
Bristol-Myers Squibb Company |
Immunomodulators
|
EP3916017A1
(en)
|
2014-12-22 |
2021-12-01 |
PD-1 Acquisition Group, LLC |
Anti-pd-1 antibodies
|
MA40662B1
(fr)
|
2014-12-23 |
2020-12-31 |
Bristol Myers Squibb Co |
Anticorps contre tigit
|
WO2016111947A2
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
MA41463A
(fr)
|
2015-02-03 |
2017-12-12 |
Anaptysbio Inc |
Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
|
US20160222060A1
(en)
|
2015-02-04 |
2016-08-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
AU2016219785B2
(en)
|
2015-02-20 |
2021-10-28 |
Ohio State Innovation Foundation |
Bivalent antibody directed against NKG2D and tumor associated antigens
|
EP3265486A4
(en)
|
2015-03-06 |
2018-11-14 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind tim3
|
CA2978942A1
(en)
|
2015-03-13 |
2016-09-22 |
Cytomx Therapeutics, Inc. |
Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
|
US9809625B2
(en)
|
2015-03-18 |
2017-11-07 |
Bristol-Myers Squibb Company |
Immunomodulators
|
CN114907481A
(zh)
|
2015-03-23 |
2022-08-16 |
震动疗法股份有限公司 |
Icos的抗体
|
MA41867A
(fr)
|
2015-04-01 |
2018-02-06 |
Anaptysbio Inc |
Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
|
MY188049A
(en)
|
2015-05-29 |
2021-11-12 |
Bristol Myers Squibb Co |
Antibodies against ox40 and uses thereof
|
DK3303394T3
(da)
|
2015-05-29 |
2020-07-06 |
Agenus Inc |
Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
CN107810011A
(zh)
|
2015-06-08 |
2018-03-16 |
豪夫迈·罗氏有限公司 |
使用抗ox40抗体治疗癌症的方法
|
WO2016197367A1
(en)
|
2015-06-11 |
2016-12-15 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
US9902772B2
(en)
|
2015-07-22 |
2018-02-27 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind LAG3
|
PT3328419T
(pt)
|
2015-07-30 |
2021-11-26 |
Macrogenics Inc |
Moléculas de ligação pd-1 e métodos de utilização
|
WO2017020291A1
(en)
|
2015-08-06 |
2017-02-09 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
EP3331901A1
(en)
|
2015-08-07 |
2018-06-13 |
Pieris Pharmaceuticals GmbH |
Novel fusion polypeptide specific for lag-3 and pd-1
|
WO2017024465A1
(en)
|
2015-08-10 |
2017-02-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
WO2017024515A1
(en)
|
2015-08-11 |
2017-02-16 |
Wuxi Biologics (Cayman) Inc. |
Novel anti-pd-1 antibodies
|
SG10201914109VA
(en)
|
2015-08-11 |
2020-02-27 |
Wuxi Biologics Cayman Inc |
Novel anti-pd-1 antibodies
|
EP3337826A1
(en)
|
2015-08-20 |
2018-06-27 |
Sutro Biopharma, Inc. |
Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies
|
AR105654A1
(es)
|
2015-08-24 |
2017-10-25 |
Lilly Co Eli |
Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
|
MA48579A
(fr)
|
2015-09-01 |
2020-03-18 |
Agenus Inc |
Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
|
KR20200087283A
(ko)
|
2015-09-25 |
2020-07-20 |
제넨테크, 인크. |
항-tigit 항체 및 이의 이용 방법
|
CN108139394B
(zh)
|
2015-10-02 |
2020-10-30 |
豪夫迈·罗氏有限公司 |
用于确定同时结合的基于细胞的fret测定法
|
WO2017055404A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies specific for pd1 and tim3
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗lag3抗體及其用途
|
US10745382B2
(en)
|
2015-10-15 |
2020-08-18 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
US10624974B2
(en)
|
2015-10-15 |
2020-04-21 |
Dingfu Biotarget Co., Ltd. |
Anti-OX40 antibody and application thereof
|
BR112018008891A8
(pt)
|
2015-11-03 |
2019-02-26 |
Janssen Biotech Inc |
anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
|
JP6931329B2
(ja)
|
2015-11-18 |
2021-09-01 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法
|
JP6925278B2
(ja)
|
2015-11-18 |
2021-08-25 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
KR102317574B1
(ko)
|
2015-11-18 |
2021-10-26 |
머크 샤프 앤드 돔 코포레이션 |
Pd1 및/또는 lag3 결합제
|
WO2017087901A2
(en)
|
2015-11-19 |
2017-05-26 |
Sutro Biopharma, Inc. |
Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
|
CA3007233A1
(en)
|
2015-12-02 |
2017-06-08 |
Agenus Inc. |
Antibodies and methods of use thereof
|
EP3383914A4
(en)
|
2015-12-02 |
2019-10-30 |
Agenus Inc. |
ANTI-OX40 ANTIBODIES AND METHODS OF USE
|
CA3006963A1
(en)
|
2015-12-03 |
2017-06-08 |
Ludwig Institute For Cancer Research Ltd. |
Anti-ox40 antibodies and methods of use thereof
|
EP3387155A4
(en)
*
|
2015-12-10 |
2019-06-12 |
Definiens AG |
METHOD FOR THE TREATMENT AND SELECTION OF PATIENTS THAT APPLY TO IMMUNE-ACTED CANCER THERAPY
|
SG11201804839WA
(en)
|
2015-12-14 |
2018-07-30 |
Macrogenics Inc |
Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
|
KR20180086502A
(ko)
|
2015-12-16 |
2018-07-31 |
머크 샤프 앤드 돔 코포레이션 |
항-lag3 항체 및 항원-결합 단편
|
CN108697776A
(zh)
|
2016-01-11 |
2018-10-23 |
阿尔莫生物科技股份有限公司 |
在产生抗原特异性cd8+t细胞中的白介素-10及其使用方法
|
WO2017132827A1
(en)
|
2016-02-02 |
2017-08-10 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
CN111491362B
(zh)
|
2016-02-02 |
2023-10-24 |
华为技术有限公司 |
确定发射功率的方法、用户设备和基站
|
WO2017134292A1
(en)
|
2016-02-04 |
2017-08-10 |
Glenmark Pharmaceuticals S.A. |
Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis
|
US10143746B2
(en)
|
2016-03-04 |
2018-12-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
SG10201601719RA
(en)
|
2016-03-04 |
2017-10-30 |
Agency Science Tech & Res |
Anti-LAG-3 Antibodies
|
US10358463B2
(en)
|
2016-04-05 |
2019-07-23 |
Bristol-Myers Squibb Company |
Immunomodulators
|
MD3443009T2
(ro)
|
2016-04-12 |
2022-02-28 |
Symphogen As |
Anticorpi anti-TIM-3 și compoziții
|
DK3458478T3
(da)
|
2016-05-18 |
2021-03-22 |
Boehringer Ingelheim Int |
Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling
|
SG11201810023QA
(en)
|
2016-05-27 |
2018-12-28 |
Agenus Inc |
Anti-tim-3 antibodies and methods of use thereof
|
SG11201811064TA
(en)
|
2016-06-20 |
2019-01-30 |
F Star Delta Ltd |
Binding molecules binding pd-l1 and lag-3
|
CN109311993B
(zh)
|
2016-06-20 |
2022-12-20 |
F-星治疗有限公司 |
Lag-3结合元件
|
JP7461741B2
(ja)
|
2016-06-20 |
2024-04-04 |
カイマブ・リミテッド |
抗pd-l1およびil-2サイトカイン
|
TWI757304B
(zh)
|
2016-06-23 |
2022-03-11 |
大陸商江蘇恆瑞醫藥股份有限公司 |
Lag-3抗體、其抗原結合片段及其醫藥用途
|
US10590105B2
(en)
|
2016-07-08 |
2020-03-17 |
Bristol-Meyers Squibb Company |
1,3-dihydroxy-phenyl derivatives useful as immunomodulators
|
AU2017297506A1
(en)
|
2016-07-14 |
2019-02-21 |
Bristol-Myers Squibb Company |
Antibodies against TIM3 and uses thereof
|
EP3498840A4
(en)
|
2016-08-15 |
2020-05-06 |
National University Corporation Hokkaido University |
ANTI-LAG-3 ANTIBODIES
|
JOP20190013A1
(ar)
|
2016-08-25 |
2019-01-31 |
Lilly Co Eli |
أجسام مضادة لـ (تي آي ام -3)
|
CN109790218B
(zh)
|
2016-08-26 |
2023-03-03 |
百济神州有限公司 |
抗tim-3抗体及其用途
|
US10144706B2
(en)
|
2016-09-01 |
2018-12-04 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
CN117586403A
(zh)
|
2016-10-11 |
2024-02-23 |
艾吉纳斯公司 |
抗lag-3抗体及其使用方法
|
JP7212821B2
(ja)
|
2016-10-13 |
2023-01-26 |
チア・タイ・ティエンチン・ファーマシューティカル・グループ・カンパニー・リミテッド |
抗lag-3抗体および組成物
|
UY37463A
(es)
|
2016-11-02 |
2018-05-31 |
Glaxosmithkline Ip No 2 Ltd |
Proteínas de unión
|
WO2018085750A2
(en)
|
2016-11-07 |
2018-05-11 |
Bristol-Myers Squibb Company |
Immunomodulators
|
WO2018118848A1
(en)
|
2016-12-20 |
2018-06-28 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
WO2018183171A1
(en)
|
2017-03-27 |
2018-10-04 |
Bristol-Myers Squibb Company |
Substituted isoquionline derivatives as immunomudulators
|
KR20190139225A
(ko)
*
|
2017-04-28 |
2019-12-17 |
머크 샤프 앤드 돔 코포레이션 |
암 치료제용 생물마커
|
JP7206222B2
(ja)
|
2017-06-23 |
2023-01-17 |
ブリストル-マイヤーズ スクイブ カンパニー |
Pd-1のアンタゴニストとして作用する免疫調節剤
|
EP3692053A1
(en)
|
2017-10-03 |
2020-08-12 |
Bristol-Myers Squibb Company |
Immunomodulators
|
JP7214752B2
(ja)
|
2018-01-23 |
2023-01-30 |
ブリストル-マイヤーズ スクイブ カンパニー |
免疫調節剤として有用な2,8-ジアシル-2,8-ジアザスピロ[5.5]ウンデカン化合物
|
JP7326306B2
(ja)
|
2018-03-01 |
2023-08-15 |
ブリストル-マイヤーズ スクイブ カンパニー |
免疫調節剤として有用な化合物
|